|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Available-for-sale investments | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease, right-of-use assets | ||||||||||||||||||||
| Financing lease, right-of-use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Current portion of financing lease liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term operating lease liability, net of current portion | ||||||||||||||||||||
| Long-term financing lease liability, net of current portion | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock, $0.001 par value per share:; 340,000,000 authorized shares as of June 30, 2026 (unaudited) and December 31, 2025; issued and outstanding shares - 98,087,425 as of June 30, 2026 (unaudited) and 98,031,104 as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total aTyr Pharma stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interest in Pangu BioPharma Limited | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
